RavindraUppaluriMDPhD
Otolaryngology (ENT) • Boston, MAHead & Neck Oncologic Surgery
Director, Head and Neck Surgical Oncology, Chief, Division of Otolaryngology Dana-Farber Cancer Institute / Brigham and Women's Hospital
Dr. Uppaluri is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
45 Francis Street
Boston, MA 02115Phone+1 617-525-3000
Education & Training
Washington University/B-JH/SLCH ConsortiumResidency, Otolaryngology - Head and Neck Surgery, 1996 - 2001- Washington University/B-JH/SLCH ConsortiumResidency, Otolaryngology - Head and Neck Surgery, 1996 - 2000
- Washington University/B-JH/SLCH ConsortiumInternship, Transitional Year, 1995 - 1996
University of Minnesota Medical SchoolClass of 1995
Certifications & Licensure
MA State Medical License 2016 - 2024
MO State Medical License 1996 - 2017- American Board of Otolaryngology - Head and Neck Surgery Otolaryngology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012
- Fellow (FACS) American College of Surgeons
- Fellow (FAAO-HNS) American Academy of Otolaryngology - Head and Neck Surgery
Clinical Trials
- GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer Start of enrollment: 2013 Feb 01
- Post Operative Adjuvant Therapy De-intensification Trial for Human Papillomavirus-related, p16+ Oropharynx Cancer Start of enrollment: 2013 Jan 10
- Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma Start of enrollment: 2015 Mar 25
Publications & Presentations
PubMed
- 450 citationsA critical function for type I interferons in cancer immunoeditingGavin P. Dunn, Allen T. Bruce, Kathleen C. F. Sheehan, Vijay Shankaran, Ravindra Uppaluri
Nature Immunology. 2005-06-12 - 83 citationsGalectin-1–driven T cell exclusion in the tumor endothelium promotes immunotherapy resistanceDhanya Nambiar, Todd A. Aguilera, Hongbin Cao, Shirley Kwok, Christina S. Kong
The Journal of Clinical Investigation. 2019-12-02 - 10 citationsTREX1 Inactivation Unleashes Cancer Cell STING-Interferon Signaling and Promotes Antitumor Immunity.Tetsuo Tani, Haritha Mathsyaraja, Marco Campisi, Ze-Hua Li, Koji Haratani
Cancer Discovery. 2024-05-01
Journal Articles
- A Deep Learning Approach to Automate Refinement of Somatic Variant Calling from Cancer Sequencing DataRavindra Uppaluri, Gavin P Dunn, Ramaswamy Govindan, S Joshua Swamidass, Todd A Fehniger, Nature
- Tumor Innate Immunity Primed by Specific Interferon-Stimulated Endogenous RetrovirusesScott Rodig, Ewa Sicinska, Thanh Uyen Barbie, David Allen Barbie, Russell William Jenkins, Ravindra Uppaluri, Rohit Thummalapalli, Jacob Sands, Nature
Press Mentions
Tumor-Infiltrating Nerves Functionally Alter Brain Circuits and Modulate Behavior in a Mouse Model of Head-and-Neck CancerSeptember 20th, 2024- In Situ Vaccination Following Intratumoral Injection of IL2 and Poly-L-lysine/Iron Oxide/CpG Nanoparticles to a Radiated Tumor SiteMay 22nd, 2023
- Temporal Analysis of Type 1 Interferon Activation in Tumor Cells Following External Beam Radiotherapy or Targeted Radionuclide TherapyOctober 22nd, 2020
- Join now to see all
Grant Support
- IFN Gamma Induced Angiostatic ChemokinesNational Cancer Institute2002–2006
Professional Memberships
- Fellow
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
